We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Target, Illumina, T-Mobile US, Xcel and Regeneron
Read MoreHide Full Article
For Immediate Release
Chicago, IL –September 23, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Target (TGT - Free Report) , Illumina (ILMN - Free Report) , T-Mobile US (TMUS - Free Report) , Xcel Energy (XEL - Free Report) and Regeneron Pharmaceuticals (REGN - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Research Reports for Target, Illumina and T-Mobile US
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Target, Illumina and T-Mobile US. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Target’s shares have outperformed the Zacks Retail- Discount & Variety industry in the year-to-date period (63.2% vs. 39.5%). The Zacks analyst thinks that the company is fast acclimatizing with the changing retail ecosystem and deploying resources to enhance omni-channel capacities, come up with new brands, remodel stores and expand same-day delivery options.
These bode well for the company that posted better-than-expected second-quarter fiscal 2019 results, wherein both the top and the bottom lines grew year over year. The company witnessed healthy traffic and impressive comparable digital channel sales. Sturdy performance prompted management to lift fiscal 2019 earnings view.
Management now envisions comparable sales to increase about 3.4% both in the third quarter and in the second half. However, we believe that incremental investments, higher wages and rise in costs due to new fulfillment options may squeeze margins.
Shares of Illumina have lost 4.4% in the past six months, outperforming the Zacks Medical - Biomedical and Genetics industry’s fall of 12.2%. The Zacks analyst believes llumina continues to put up a robust performance across a broad range of sequencing applications.
The launch of Veriseq NIPT v2 and the company’s partnership with AnchorDx in the second quarter also drive optimism. Over the past year, Illumina’s shares have been outperforming the industry it belongs to. With respect to quarterly results, Illumina exited the second quarter of 2019 on a solid note, with earnings and revenues beating the Zacks Consensus Estimate.
It is encouraging to note that revenues grew across the company’s high and low throughput categories. On the flip side, contraction in both margins and a year-over-year decline in Service and Other Revenues are concerns.
T-Mobile US’ shares have gained 7% in the past three months, underperforming the Zacks National Wireless industry’s rise of 7.9% over the same period. The Zacks analyst believes that the New T-Mobile will have about 127 million customers and a strong closing balance sheet, and is expected to heighten competition in the 5G space.
T-Mobile has cleared most of the regulatory and shareholder approvals for its game-changing merger with Sprint. T-Mobile continues to invest in its network and prepare for nationwide 5G with the aggressive rollout of its 600 MHz spectrum. The wireless carrier has introduced 5G millimeter wave network in six cities including New York and Los Angeles.
However, a highly competitive and saturated U.S. wireless market remains a major headwind. Intensifying competition is likely to limit its ability to attract and retain customers and may affect operating results. The company launched several low-priced service plans which have enhanced its revenues, but not significantly improved the bottom line.
Other noteworthy reports we are featuring today include Xcel Energy and Regeneron Pharmaceuticals.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.6% per year.
These 7 were selected because of their superior potential for immediate breakout.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Target, Illumina, T-Mobile US, Xcel and Regeneron
For Immediate Release
Chicago, IL –September 23, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Target (TGT - Free Report) , Illumina (ILMN - Free Report) , T-Mobile US (TMUS - Free Report) , Xcel Energy (XEL - Free Report) and Regeneron Pharmaceuticals (REGN - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Research Reports for Target, Illumina and T-Mobile US
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Target, Illumina and T-Mobile US. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Target’s shares have outperformed the Zacks Retail- Discount & Variety industry in the year-to-date period (63.2% vs. 39.5%). The Zacks analyst thinks that the company is fast acclimatizing with the changing retail ecosystem and deploying resources to enhance omni-channel capacities, come up with new brands, remodel stores and expand same-day delivery options.
These bode well for the company that posted better-than-expected second-quarter fiscal 2019 results, wherein both the top and the bottom lines grew year over year. The company witnessed healthy traffic and impressive comparable digital channel sales. Sturdy performance prompted management to lift fiscal 2019 earnings view.
Management now envisions comparable sales to increase about 3.4% both in the third quarter and in the second half. However, we believe that incremental investments, higher wages and rise in costs due to new fulfillment options may squeeze margins.
(You can read the full research report on Target here >>>)
Shares of Illumina have lost 4.4% in the past six months, outperforming the Zacks Medical - Biomedical and Genetics industry’s fall of 12.2%. The Zacks analyst believes llumina continues to put up a robust performance across a broad range of sequencing applications.
The launch of Veriseq NIPT v2 and the company’s partnership with AnchorDx in the second quarter also drive optimism. Over the past year, Illumina’s shares have been outperforming the industry it belongs to. With respect to quarterly results, Illumina exited the second quarter of 2019 on a solid note, with earnings and revenues beating the Zacks Consensus Estimate.
It is encouraging to note that revenues grew across the company’s high and low throughput categories. On the flip side, contraction in both margins and a year-over-year decline in Service and Other Revenues are concerns.
(You can read the full research report on Illumina here >>>).
T-Mobile US’ shares have gained 7% in the past three months, underperforming the Zacks National Wireless industry’s rise of 7.9% over the same period. The Zacks analyst believes that the New T-Mobile will have about 127 million customers and a strong closing balance sheet, and is expected to heighten competition in the 5G space.
T-Mobile has cleared most of the regulatory and shareholder approvals for its game-changing merger with Sprint. T-Mobile continues to invest in its network and prepare for nationwide 5G with the aggressive rollout of its 600 MHz spectrum. The wireless carrier has introduced 5G millimeter wave network in six cities including New York and Los Angeles.
However, a highly competitive and saturated U.S. wireless market remains a major headwind. Intensifying competition is likely to limit its ability to attract and retain customers and may affect operating results. The company launched several low-priced service plans which have enhanced its revenues, but not significantly improved the bottom line.
(You can read the full research report on T-Mobile US here >>>).
Other noteworthy reports we are featuring today include Xcel Energy and Regeneron Pharmaceuticals.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.6% per year.
These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.